CelluTarget · Multifocal Motor Neuropathy · Treatments
◎ Investigational

Cyclophosphamide (second-line, off-label)

1
Evidence entries
0
Clinical trials
Overview
Treatment Details
Mechanism of Action
Alkylating immunosuppressant; considered when IVIG becomes insufficient.
Dosing Notes
Dosing individualized; used off-label for MMN.
Treatment Type
pharmaceutical
Clinical Evidence
What the Evidence Shows
Each finding below is linked to its primary source. Confidence levels reflect the quality and quantity of available evidence — not CelluTarget's endorsement of any treatment.
High: Supported by multiple robust studies or regulatory approval
Moderate: Supported by limited controlled studies or consistent case series
Low: Based on case reports, expert opinion, or early-phase data only
Low ConfidenceBased on case reports, expert opinion, or early-phase data only
EFNS/PNS guideline: cyclophosphamide is a possible immunosuppressive option (among several) if IVIG is not or not sufficiently effective. No placebo-controlled trials exist; based on case reports and non-randomized data.
Verified Jul 2026
Peer Reviewed
EFNS/PNS Guideline on management of multifocal motor neuropathy (joint task force report)
Published March 2006
View source ↗
Clinical Trials
Linked Trials
No clinical trials linked to this treatment yet.